摘要
Abstract
Objective To evaluate the efficacy of memantine combined with rivastigmine initiated simultaneous versus rivastigmine mono therapy on ADL(20 item version in China) in the mild-to-moderate stage of Alzheimer's disease.Methods 122 patients who met the standards were randomly divided into rivastigmine group and memantine plus rivastigmine combination group. At baseline and after 12 and 24 weeks treatment,the patients were assessed by mini-mental state examination(MMSE),activity of daily living scale(ADL),Alzheimer's disease assessment scale - cognitive subscales (ADAS-cog),the Relevant Outcome Scale for Alzheimer's Disease(ROSA),Zarit caregiver burden scale(ZBI) and the scores of MMSE,ADL,ADAS-cog,ROSA and ZBI were compared respectively. Results (1)The scores of MMSE,ADL,ADAS-cog,ROSA and ZBI after 24 weeks treatment were significant difference compared with the baseline(P<0.05).(2)The scores of MMSE and ROSA after 24 weeks treatment were lower in rivastigmine group than in the combination group,the scores of ADL, ADAS - cog and ZBI were higher than in the combination group,the improved scores of each scales were significantly better in the combination group than in rivastigmine group (P<0.05),but the score of PADL had no difference(P>0.05),and there was no statistical significance. ConclusionRivastigmine and memantine combined with rivastigmine may be improve the clinical effects in the treatment of mild-to-moderate AD. Memantine combined with rivastigmine to treat patients with mild-to-moderate AD may be improve daily life ability better than rivastigmine group. During theperiod of treatment, combined treatment group’s adverse reactions do not increase.Different neuropsychological scales have an auxiliary significance to the diagnosis and the clinical effects of Alzheimer’s disease.关键词
阿尔茨海默病/美金刚/卡巴拉汀/日常生活能力Key words
Alzheimer’s disease/Memantine/Rivastigmine/Activities of Daily Living分类
医药卫生
